This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Life Sciences

In the past several years, China's domestic pharmaceutical consumption has increased dramatically. Pharmaceutical industry sales revenue has grown an average of 21.4 percent annually.  Driven by strong economic growth, increasing urbanization and the health demands of an aging population, China's pharmaceutical market is projected to become one of the world’s largest. By 2020, China is expected to grow its pharmaceutical market volume to $220 billion USD, becoming the second-largest market after the United States.

Deloitte China Life Sciences practice

As a member of the Deloitte Global Life Sciences Industry network, Deloitte China Life Sciences Industry practice works closely with our global counterparts to provide industry players in pharmaceuticals, biotechnology, medical devices, pharmaceutical distribution and CRO with full and feasible solutions with new thinking leveraging our global industry's best practices as well as our knowledge and rich experience in the local market.

Featured highlight

  • Top JV Issues for Pharmaceutical Companies in China
    Establishing a joint venture in China is a complex and time-consuming task, and there is no guarantee of success or even survival. It is critical for pharma executives to fully understand various pitfalls and manage the partnership for success.
  • 2014 Global Life Sciences Outlook
    The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
  • Transforming Medical Affairs in China
    Rethinking the role and effectiveness of the Medical Affairs function has become an urgent priority for pharmaceutical companies in China. The report presents our perspective on these challenges and how they can be successfully overcome.
  • Health care reform and life sciences: Threat, opportunity or both?
    Exploring how nearly 300 senior life science executives are meeting the challenges and opportunities of global health care reforms, and the national differences through case studies of China, Brazil and Germany.
  • Know your risks
    Emerging markets, third party intermediaries, and life sciences industry
  • The next phase: Opportunities in China's pharmaceuticals market
    This report focuses in particular on pharmaceuticals companies, both domestic and foreign, and their activities in the China market—all from the viewpoint of prospective investors.

Featured contents

  • ExternalURL
    R&D leadership development in today’s environment
    Understanding the business of science
  • ExternalURL
    Winning in Life Sciences
    Deloitte’s key propositions to the Life Science and Healthcare industries many and varied challenges.
  • ExternalURL
    Critical Priorities for the CIO
    Deloitte has identified 10 priority areas for the CIO spanning IT effectiveness, IT efficiency and IT Capabilities

Related links

  • ExternalURL
    Deloitte global life sciences
    Global reach that you can count on
  • ExternalURL
    Deloitte China services
    Our full range of services
Share your comments

 

Stay connected